Eleni Efstathiou

AnCan presentation by Dr. Eleni Efstathiou - 12/19/2022

Eleni Efstathiou, MD, PhD, elaborates on the role of chemotherapy in mCRPC

Eleni Efstathiou, MD, PhD, discusses the prostate-specific membrane antigen (PSMA) lutetium

Eleni Efstathiou, MD, PhD, offers a message for patients on clinical progress in prostate cancer

Eleni Efstathiou, MD, PhD, offers opinion on the ACIS clinical trial

Eleni Efstathiou, MD, PhD, considers the role of precision medicine in prostate cancer

Eleni Efstathiou, MD, PhD, on whether genetic mutation data impacts the treatment of prostate cancer

Eleni Efstathiou, MD, PhD, discusses the CheckMate 9ER clinical trial presented at ESMO 2020

Eleni Efstathiou, MD, PhD, provides perspective on the IPATential150 study in mCRPC

Eleni Efstathiou, MD, PhD, on the practice-changing potential of the PROfound study from ESMO 2020

Eleni Efstathiou, MD, PhD, regarding the preliminary analysis of belzutifan & cabozantinib in ccRCC

Eleni Efstathiou, MD, PhD, regarding the PROSPER clinical trial from ASCO GU 2021

Eleni Efstathiou, MD, PhD, shares thoughts on the TROPHY-U-01 clinical study presented at ESMO 2020

Eleni Efstathiou, MD, PhD, offers opinion on whether CheckMate 9ER is practice-changing

Eleni Efstathiou, MD, PhD, regarding patients more likely to respond to nivolumab + cabozantinib

Making advances in prostate cancer

Biomarkers for the management of prostate cancer

GU Debates 2019: Updates on genitourinary cancers (2/2)

Personalizing Prostate Cancer Treatment | Houston Methodist

October 22, 2024

Abiraterone: a step forward in the treatment of prostate cancer

ASCO GU 2022 - Janssen Highlights Niraparib Combo Data

EAU guidelines for treating patients with advanced prostate cancer

Introducing biomarkers for the management of patients with prostate cancer

welcome to shbcf.ru